Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma

February 15, 2017
Colorectal Cancer
Alexander Hantel, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

To test the effectiveness of the research study drug, Pembrolizumab (MK-3475) compared to other standard treatment chemotherapy drugs of the study doctor’s choice for Stage IV Colorectal cancer.

Sponsor: Merck Sharp & Dohme Corp., (a subsidiary of Merck & Co. Inc.)

  • Male or female who is over the age of 18
  • Have locally confirmed MMR deficient or microsatellite instability high stage IV colorectal carcinoma
  • No prior systemic therapy for stage IV CRC, but may have received prior adjuvant chemotherapy as long as it was completed at least 6 months prior to randomization
  • No radiation therapy within 4 weeks prior to randomization
  • No prior therapy with an immune therapy drug


Accepting Participants
Kathy Seymour, BSN